Stephanie L. Silveria

Intra-tumoral Treg ablation enhances NK cell-mediated tumor control by restoring IL-2 production, effective against both MHC I+ and MHC I- cancers without systemic toxicity.

This study shows targeting FSP1 in regulatory T cells disrupts their immunosuppression, enhancing anti-tumor immunity without causing autoimmunity.

This study shows that p53 activity, regulated epigenetically, maintains intestinal Treg identity and prevents inflammation by preventing Foxp3 loss in Th17 environments.

This study shows that increased EZH2 activity in regulatory T cells enhances their effector differentiation and autoimmunity suppression capacity.